Natural history of t(11;14) multiple myeloma

A. Lakshman; M. Alhaj Moustafa; S. V. Rajkumar; A. Dispenzieri; M. A. Gertz; F. K. Buadi; M. Q. Lacy; D. Dingli; A. L. Fonder; S. R. Hayman; M. A. Hobbs; W. I. Gonsalves; Y. L. Hwa; P. Kapoor; N. Leung; R. S. Go; Y. Lin; T. V. Kourelis; J. A. Lust; S. J. Russell; S. R. Zeldenrust; R. A. Kyle; S. K. Kumar

doi:10.1038/leu.2017.204

Natural history of t(11;14) multiple myeloma

A. Lakshman, M. Alhaj Moustafa, S. V. Rajkumar, A. Dispenzieri, M. A. Gertz, F. K. Buadi, M. Q. Lacy, D. Dingli, A. L. Fonder, S. R. Hayman, M. A. Hobbs, W. I. Gonsalves, Y. L. Hwa, P. Kapoor, N. Leung, R. S. Go, Y. Lin, T. V. Kourelis, J. A. Lust, S. J. RussellS. R. Zeldenrust, R. A. Kyle, S. K. Kumar

Research output: Contribution to journal › Article › peer-review

36 Scopus citations

Abstract

Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

Original language	English (US)
Pages (from-to)	131-138
Number of pages	8
Journal	Leukemia
Volume	32
Issue number	1
DOIs	https://doi.org/10.1038/leu.2017.204
State	Published - Jan 2018

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2017.204

Cite this

Lakshman, A., Alhaj Moustafa, M., Rajkumar, S. V., Dispenzieri, A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Hwa, Y. L., Kapoor, P., Leung, N., Go, R. S., Lin, Y., Kourelis, T. V., Lust, J. A., ... Kumar, S. K. (2018). Natural history of t(11;14) multiple myeloma. Leukemia, 32(1), 131-138. https://doi.org/10.1038/leu.2017.204

Lakshman, A, Alhaj Moustafa, M, Rajkumar, SV , Dispenzieri, A , Gertz, MA, Buadi, FK, Lacy, MQ , Dingli, D, Fonder, AL, Hayman, SR, Hobbs, MA, Gonsalves, WI, Hwa, YL, Kapoor, P, Leung, N, Go, RS, Lin, Y , Kourelis, TV, Lust, JA, Russell, SJ, Zeldenrust, SR, Kyle, RA & Kumar, SK 2018, 'Natural history of t(11;14) multiple myeloma', Leukemia, vol. 32, no. 1, pp. 131-138. https://doi.org/10.1038/leu.2017.204

@article{4138c60b1d1a42a6b9550a46dd676414,

title = "Natural history of t(11;14) multiple myeloma",

abstract = "Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.",

author = "A. Lakshman and {Alhaj Moustafa}, M. and Rajkumar, {S. V.} and A. Dispenzieri and Gertz, {M. A.} and Buadi, {F. K.} and Lacy, {M. Q.} and D. Dingli and Fonder, {A. L.} and Hayman, {S. R.} and Hobbs, {M. A.} and Gonsalves, {W. I.} and Hwa, {Y. L.} and P. Kapoor and N. Leung and Go, {R. S.} and Y. Lin and Kourelis, {T. V.} and Lust, {J. A.} and Russell, {S. J.} and Zeldenrust, {S. R.} and Kyle, {R. A.} and Kumar, {S. K.}",

year = "2018",

month = jan,

doi = "10.1038/leu.2017.204",

language = "English (US)",

volume = "32",

pages = "131--138",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Natural history of t(11;14) multiple myeloma

AU - Lakshman, A.

AU - Alhaj Moustafa, M.

AU - Rajkumar, S. V.

AU - Dispenzieri, A.

AU - Gertz, M. A.

AU - Buadi, F. K.

AU - Lacy, M. Q.

AU - Dingli, D.

AU - Fonder, A. L.

AU - Hayman, S. R.

AU - Hobbs, M. A.

AU - Gonsalves, W. I.

AU - Hwa, Y. L.

AU - Kapoor, P.

AU - Leung, N.

AU - Go, R. S.

AU - Lin, Y.

AU - Kourelis, T. V.

AU - Lust, J. A.

AU - Russell, S. J.

AU - Zeldenrust, S. R.

AU - Kyle, R. A.

AU - Kumar, S. K.

PY - 2018/1

Y1 - 2018/1

N2 - Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

AB - Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current therapies. We identified 365 patients with t(11;14), and 730 matched controls:132 patients with non-(11;14) translocations and 598 patients with no chromosomal translocation. The median progression-free survival for the three groups were 23.0 (95% confidence interval (CI), 20.8-27.6), 19.0 (95% CI, 15.8-22.7) and 28.3 (95% CI, 25.7-30.6) months, respectively (P<0.01). The median overall survival (OS) for t(11;14), non-(11;14) translocation and no-translocation groups were 74.4 (95% CI, 64.8-89.3), 49.8 (95% CI, 40.0-60.6) and 103.6 (95% CI, 85.2-112.3) months, respectively (P<0.01). Excluding those with 17p abnormality, the median OS in the three groups were 81.7 (95% CI, 67.0-90.7), 58.2 (95% CI, 47.0-76.4) and 108.3 (95% CI, 92.4-140.1) months, respectively (P<0.01). The above relationship held true in patients with age <65 years, international staging system (ISS) I/II stage or those who received novel agent-based induction. Advanced age (hazard ratio (HR): 1.98), 17p abnormality (HR: 2.2) and ISS III stage (HR: 1.59) at diagnosis predicted reduced OS in patients with t(11;14). These results suggest that outcomes of t(11;14) MM are inferior to other standard risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85045980418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045980418&partnerID=8YFLogxK

U2 - 10.1038/leu.2017.204

DO - 10.1038/leu.2017.204

M3 - Article

C2 - 28655925

AN - SCOPUS:85045980418

SN - 0887-6924

VL - 32

SP - 131

EP - 138

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Natural history of t(11;14) multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this